AIDS TREATMENT NEWS #234, November 3, 1995
John S. James
The volunteers were randomly assigned to receive either peptide T (intranasally, up to six mg/day) or placebo for six months; for the next six months, everyone was given peptide T, and they could continue the medication beyond one year if they wanted. Cognitive impairment (which includes difficulties with memory, attention, language, problem solving, spatial ability, and visual-motor coordination) was measured by standard neuropsychological tests. The treatment group showed no statistically significant improvement compared to the control group.
The study also found no toxicity from peptide T.
Recruiting for this study began in March 1991. It took a long time to find volunteers -- probably because AIDS-related cognitive impairment is less common than had been expected, and because it can often be treated effectively with AZT.
This clinical trial was conducted by the U.S. National Institute of Mental Health, with additional funding from the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
951103
ATN23410
Copyright © 1995 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .